Melanoma - Targeted Therapeutics

The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. In the current alternatives for the treatment of malignant melanoma several combinatory treatments are used. Melanoma drug development has and will continue to have a strong focus on target therapy such as cancer vaccines, monoclonal antibodies, biological drugs, antiangiogenesis, apoptotic inducers and gene therapy. In recent years, immunologic strategies including tumor vaccine and adjuvant therapy with interferon-alfa have been attempted to improve survival of patients with more advanced malignant melanoma. Another emerging strategy in anticancer therapy is the targeting of chemotherapy resistance by overcoming the antiapoptosis mechanisms of cancer cells and antiangiogenesis.

This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. No less than 68 approved drugs and drug candidates have been studied. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for melanoma and specially the late stage pipeline it has been clear that four major therapeutic strategies generated the most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments.

This report covers the latest on:

Analysis of current treatment and key therapeutic strategies

Progress analysis of on more than 50 pipeline products, including emerging and hot pre-clinical data, discontinued projects, clinical trial information, commercial potential and limiting factors.

Enables competitive landscape analysis

Achievements from the most important companies in melanoma R&D

Example of drugs included in this analysis:

ABX MA1, Alfanative , ALLOVECTIN-7, AP 12009, Avastin, BAY 504798, Canvaxin, Carboplatin, Carmustine, Ceplene Maxamine, Cisplatin, CP 4055, Dacarbazine, Dexosome, Didemnin B, Ecromeximab, Elea Vaccine, EMD 273063, Enhanzyn, F 50040, Genasense, GMK, GV 1001, GVAX, Iboctadekin, ILX 651, INGN 241, INO 1001, Intron A, Kahalalide F, Karenitecin, KOS 953, Lenalidomide, Lomeguatrib, MDX-010, Melacine, Melphalan, MJV 101, M-VAX, NOVOVAC-M1, NY-ESO-1 ISCOMS, Oncophage, OncoVax, OncoVEXGM-CSF, Paclitaxel, PD 0325901, Peginterferon alfa-2b, Pivanex, Proleukin , ProMune, QS-21, SB 249553, SB 715992, Sorafenib, Talabostat, Tamoxifen, Temozolomide, Temozolomide, Uvidem, Vinblastine/Vinorelbine, Virulizin, Vitaxin, Zadaxin

July 2007 Pages 197
Table of Contents
Price: $2,999.00 / GBP1,499.50